What Is Mesembrenone?
Mesembrenone is the second most abundant mesembrane alkaloid in Kanna (Sceletium tortuosum), typically present alongside mesembrine, mesembranone, and mesembranool. While mesembrine receives the most research attention, mesembrenone contributes meaningfully to the overall pharmacological profile of whole Kanna preparations. Understanding this compound is important for anyone seeking to appreciate the full complexity of Kanna’s effects.
Structurally, mesembrenone differs from mesembrine by the presence of an additional double bond in its ring system, creating a conjugated enone structure. This seemingly minor structural difference produces measurable changes in receptor binding affinity and selectivity, resulting in a qualitatively different pharmacological contribution to the Kanna alkaloid mixture.
Mesembrenone Chemical Profile
- Molecular formula: C17H19NO3
- Molecular weight: 285.34 g/mol
- Chemical class: Mesembrane alkaloid (enone variant)
- Structural distinction: Contains C-7/C-7a double bond absent in mesembrine
- Natural source: Sceletium tortuosum (Kanna)
- Typical proportion: 15–30% of total alkaloid content in fermented material
Mechanism of Action
Serotonin Transporter Inhibition
Like mesembrine, mesembrenone inhibits the serotonin transporter (SERT), but with notably lower affinity. Where mesembrine shows nanomolar binding (Ki approximately 1.4 nM), mesembrenone typically demonstrates micromolar affinity—approximately 100 to 1,000 times weaker. This means mesembrenone contributes a milder, more moderate serotonergic effect compared to its more potent sibling alkaloid.
This reduced SERT affinity is not necessarily a limitation. In the context of whole-plant preparations, the presence of a weaker SERT inhibitor alongside a potent one may help modulate the overall serotonergic tone, potentially reducing the sharp onset and peak effects that a single potent compound might produce. This buffering effect is one proposed mechanism for why traditional whole-plant Kanna preparations may feel smoother than isolated mesembrine.
PDE4 Inhibition
Mesembrenone demonstrates more potent PDE4 inhibitory activity relative to its SERT inhibition compared to mesembrine. In some assay systems, mesembrenone’s PDE4 inhibition is comparable to or even exceeds that of mesembrine, despite its weaker serotonin transporter effects. This makes mesembrenone the primary PDE4-active component in certain Kanna preparations.
The practical implication is that mesembrenone may contribute disproportionately to the cognitive and anti-inflammatory effects attributed to Kanna, while contributing less to the acute mood-elevating effects driven by serotonin reuptake inhibition.
Additional Receptor Interactions
Preliminary receptor screening data suggests mesembrenone may interact with VMAT2 (vesicular monoamine transporter 2), the protein responsible for packaging monoamines into synaptic vesicles. VMAT2 inhibition could theoretically affect dopamine, norepinephrine, and serotonin packaging, though the clinical relevance of this interaction at the concentrations found in Kanna preparations remains unclear.
The Entourage Effect in Kanna
The concept of an “entourage effect”—where multiple compounds in a whole-plant preparation produce effects different from any single isolated compound—is particularly relevant to Kanna. The interplay between mesembrine (potent SERT inhibitor), mesembrenone (moderate SERT inhibitor with strong PDE4 activity), mesembranone (a precursor that converts during fermentation), and mesembranool (a minor sedative alkaloid) creates a composite pharmacological profile that no single compound replicates. This is one reason why traditional fermented preparations may produce subjectively different effects compared to purified alkaloid extracts.
Mesembrenone vs. Mesembrine: Key Differences
| Property | Mesembrine | Mesembrenone |
|---|---|---|
| SERT affinity | Very high (Ki ~1.4 nM) | Moderate (micromolar range) |
| PDE4 inhibition | Significant | Comparable or stronger |
| Primary contribution | Mood elevation, anxiolysis | Cognitive effects, anti-inflammatory |
| Onset character | More acute, noticeable | Subtler, more gradual |
| Typical proportion | 40–60% of total alkaloids | 15–30% of total alkaloids |
Effects and Functional Contributions
Because mesembrenone is not typically consumed in isolation, its effects are best understood as contributions to the overall Kanna experience rather than standalone properties.
- Cognitive clarity: The PDE4 inhibitory activity of mesembrenone likely contributes to the mental clarity and enhanced focus that many Kanna users report, particularly at moderate doses
- Anti-inflammatory potential: PDE4 inhibition reduces pro-inflammatory signaling cascades, suggesting mesembrenone may contribute to Kanna’s traditional use for general wellness
- Modulation of mood effects: The moderate serotonergic contribution may help extend and smooth the mood-elevating effects of mesembrine in whole-plant preparations
- Potential neuroprotective effects: cAMP elevation through PDE4 inhibition supports neuronal survival pathways (CREB signaling, BDNF expression) relevant to long-term brain health
The Role of Fermentation
Traditional Kanna fermentation directly affects mesembrenone content. During the anaerobic fermentation process, enzymatic and non-enzymatic reactions convert mesembranone (an oxidized precursor) into mesembrine and mesembrenone through reduction and isomerization reactions. Unfermented Kanna contains higher proportions of mesembranone and lower proportions of mesembrine and mesembrenone.
This is why traditionally fermented Kanna is considered superior to raw plant material—the fermentation process optimizes the alkaloid ratio toward the more pharmacologically active forms. Modern standardized extracts aim to replicate or exceed the alkaloid ratios achieved through traditional fermentation.
Safety Considerations
The safety considerations for mesembrenone largely parallel those of mesembrine, given their shared mechanism classes.
- Serotonergic drug interactions: Although mesembrenone is a weaker SERT inhibitor than mesembrine, it still carries interaction risk with SSRIs, SNRIs, MAOIs, and other serotonergic medications. These combinations should be avoided.
- Gastrointestinal effects: PDE4 inhibition is associated with nausea in clinical pharmacology. This may contribute to the mild nausea some users experience when initiating Kanna use.
- Cardiovascular considerations: cAMP elevation via PDE4 inhibition can affect cardiac function. Individuals with heart conditions should seek medical advice before using Kanna products.
- Dose sensitivity: In whole-plant preparations, the combined activity of mesembrine and mesembrenone means the effective dose reflects the sum of both compounds’ contributions. Starting low is essential.
Research Landscape
Mesembrenone is less studied than mesembrine as an isolated compound. Most pharmacological characterization has occurred in the context of Kanna alkaloid mixture analysis rather than dedicated mesembrenone studies. Key research contributions include receptor binding profiling, HPLC quantification methods for Kanna alkaloid mixtures, and comparative pharmacology studies examining the relative contributions of individual alkaloids to Kanna’s overall activity.
Future research directions include dedicated in vivo studies of mesembrenone, investigation of its specific cognitive effects through PDE4 pathways, and potential applications in neuroinflammatory conditions where PDE4 inhibition has shown preclinical promise.
References
- Harvey, A.L. et al. “Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum.” Journal of Ethnopharmacology, 2011.
- Smith, M.T. et al. “Psychoactive constituents of the genus Sceletium.” Journal of Ethnopharmacology, 1996.
- Gericke, N. & Viljoen, A.M. “Sceletium—a review update.” Journal of Ethnopharmacology, 2008.
- Krstenansky, J.L. “Mesembrine alkaloids: review of their occurrence, chemistry, and pharmacology.” Journal of Ethnopharmacology, 2017.
- Loria, M.J. et al. “Effects of Sceletium tortuosum in rats.” Journal of Ethnopharmacology, 2014.